Form 10-Q Tarsus Pharmaceuticals, For: Mar 31

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. WDC
3. DECK
4. BYD
5. SPOT
6. FIX
7. BE
8. TSCO
9. WCN
10. NDAQ

Go back to Form 10-Q Tarsus Pharmaceuticals, For: Mar 31

Tarsus Pharmaceuticals (TARS) PT Raised to $63 at BofA Securities

May 10, 2024 5:24 AM EDT

BofA Securities analyst Jason Gerberry raised the price target on Tarsus Pharmaceuticals (NASDAQ: TARS) to $63.00 (from $60.00) while maintaining a Buy rating.

The analyst comments "Tarsus reported strong 1Q results with sales of Xdemvy (demodex blepharitis) meaningfully outperforming expectations ($25m vs. $17m cons).... More